Genentech, a member of the Roche Group, announced that a detailed analysis of its Phase III REGENCY trial of Gazyva® (obinutuzumab) in people with acti...
The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal ...
NeuFit is revolutionizing neurological rehabilitation with its innovative approach that integrates advanced diagnostics and therapeutic technolo...
Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced that the New England Journal of Medicine (NEJ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clini...
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tre...
Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, announced that it is col...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) announced an exclusive, global license agreement ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a...
PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced it has entered a strategic partnership with&...
HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone receptors for estrogen and/or progeste...
Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomid...
© 2025 Biopharma Boardroom. All Rights Reserved.
